Semaglutide: What to Know Before You Take It
Also known as Ozempic, Wegovy, Rybelsus
Other names: ozempic, wegovy, rybelsus
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management. It enhances insulin secretion, slows gastric emptying, and reduces appetite through central nervous system pathways.
FDA boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).
In plain language
What Semaglutide is used for
- Type 2 diabetes glycemic control
- Chronic weight management (BMI ≥30, or ≥27 with weight-related condition)
- Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease
Taking this medicine
How it is administered
- Subcutaneous injection (weekly)
- Oral tablet (daily)
Read before you decide
Risks and precautions
Risks and warnings
- Nausea, vomiting, diarrhea, abdominal pain, constipation
- Risk of thyroid C-cell tumors (animal data; human relevance unknown — black box warning)
- Pancreatitis (rare)
- Hypoglycemia when combined with insulin or sulfonylureas
Who should not take it
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planned pregnancy
- Breastfeeding
Medication review
Semaglutide drug interactions
FDA safety data
Most-reported side effects
Based on 82,911 FAERS reports. Reports do not prove the drug caused the effect.
Regulatory record
FDA recalls (5)
Presence of Particulate Matter: Hair was found in a prefilled syringe
Recalling firm: Novo Nordisk Inc.
Presence of Particulate Matter: Hair was found in a prefilled syringe
Recalling firm: Novo Nordisk Inc.
Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.
Recalling firm: Cardinal Health Inc.
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Recalling firm: Novo Nordisk Inc
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalling firm: Cardinal Health Inc.
Common questions
Patient questions
Is semaglutide FDA-approved?
Yes. Semaglutide is FDA-approved under the brand names Ozempic (injectable, type 2 diabetes), Wegovy (injectable, chronic weight management), and Rybelsus (oral tablet, type 2 diabetes). A licensed provider must evaluate whether it is appropriate for you before prescribing.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are approved for different indications at different doses. Ozempic is indicated for type 2 diabetes; Wegovy is indicated for chronic weight management at a higher maintenance dose. A provider determines which, if either, is appropriate.
What are the most common side effects of semaglutide?
The most commonly reported side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These are most common when starting or increasing the dose and often improve over time.
Related medications
Explore treatment hubs
Access and affordability
Ways to save on Semaglutide
For eligible patients using Novo Nordisk medicines; a Patient Assistance Program provides free medicine to qualifying patients who are U.S. citizens/legal residents, uninsured or on Medicare, and meet income limits. Savings cards are also available for commercially insured patients.
Visit programThis information is educational — not medical advice.
This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.
Sources & References
- FDA structured product labeling for Semaglutide
- U.S. Food & Drug Administration — openFDA Drug Labeling API
- U.S. National Library of Medicine — RxNorm drug nomenclature
- FDA label: Ozempic (semaglutide injection)
- FDA label: Wegovy (semaglutide injection)
- NIH MedlinePlus: Semaglutide injection
Learn more about where our data comes from and how we write and review medical content.